↓ Skip to main content

Dove Medical Press

Hepatitis C in the Russian Federation: challenges and future directions

Overview of attention for article published in Hepatic medicine evidence and research, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#8 of 116)
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

blogs
1 blog
twitter
17 X users

Readers on

mendeley
32 Mendeley
Title
Hepatitis C in the Russian Federation: challenges and future directions
Published in
Hepatic medicine evidence and research, May 2016
DOI 10.2147/hmer.s50172
Pubmed ID
Authors

Sergey Mukomolov, Galina Trifonova, Irina Levakova, Daria Bolsun, Eugenia Krivanogova

Abstract

Hepatitis C virus (HCV) infection is one of the most prevalent health problems in the world. Official registration of HCV infections in the Russian Federation started in 1994. Two clinical forms of infection - acute and chronic hepatitis C - are registered separately. Moreover, the HCV national surveillance system also includes reports from laboratories on results from testing ∼20 population risk groups for antibodies to HCV; approximately 15-16 million tests are performed annually. Modern epidemiological features of HCV infection in the Russian Federation are characterized by low incidence of the acute form of infection (acute HCV; one to two per 100,000) and a dramatic increase in chronic HCV (CHCV) cases. In 2013, the average nationwide rate of newly detected CHCV cases was 39.3/100,000. In the same year, the prevalence of CHCV demonstrating an accumulation of chronically infected patients in the country was much higher - 335.8/100,000. Four risk groups were identified as greatly affected by HCV, which were demonstrated by a high prevalence of antibodies to HCV: newborns from chronically infected women, persons from correctional facilities, patients with chronic liver diseases, and clients from clinics for sexually transmitted disease patients and drug users. It was found that several HCV genotypes circulated in different regions of the country; HCV1b had a prevalence of 55%-80% in almost every part of the country. However, in St Petersburg during the final decade of the last century and from 2001-2005, HCV3a subtype expanded circulation among young people due to increased intravenous drug addiction. Intravenous drug users were the major cause of a higher registration of double infection, with two different virus subtypes, and the appearance in Russia of new recombinant virus RF_2k/1b. It can be concluded that CHCV infection should be a focus of the health care system in Russia because serious epidemics of liver cirrhosis and hepatocellular carcinoma will be seen in the near future that will require urgent preventive and therapeutic measures.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 22%
Student > Bachelor 5 16%
Researcher 4 13%
Student > Ph. D. Student 3 9%
Student > Doctoral Student 2 6%
Other 3 9%
Unknown 8 25%
Readers by discipline Count As %
Medicine and Dentistry 8 25%
Nursing and Health Professions 3 9%
Immunology and Microbiology 3 9%
Biochemistry, Genetics and Molecular Biology 1 3%
Psychology 1 3%
Other 5 16%
Unknown 11 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2016.
All research outputs
#2,186,981
of 25,371,288 outputs
Outputs from Hepatic medicine evidence and research
#8
of 116 outputs
Outputs of similar age
#34,731
of 311,861 outputs
Outputs of similar age from Hepatic medicine evidence and research
#2
of 3 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 116 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,861 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.